Earnings Feed
Start Free
Home/Filings/4/0001030653-09-000016
4//SEC Filing

CURAGEN CORP 4

Accession 0001030653-09-000016

CIK 0001030653operating
View on SEC.govCompany Profile

Filed

Oct 4, 8:00 PM ET

Accepted

Oct 5, 4:00 PM ET

Size

14.6 KB

Accession

0001030653-09-000016

Insider Transaction Report

Form 4
Period: 2009-10-01
CURAGEN CORPCRGN
DEVITA VINCENT
Director
Transactions
  • Disposition to Issuer

    Common Stock

    2009-10-01−30,000→ 0 total
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2009-10-01−15,000→ 0 total
    Exercise: $0.69Exp: 2010-10-01→ Common Stock (15,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2009-10-01−15,000→ 0 total
    Exercise: $1.09Exp: 2010-10-01→ Common Stock (15,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2009-10-01−35,000→ 0 total
    Exercise: $0.57Exp: 2010-10-01→ Common Stock (35,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2009-10-01−15,000→ 0 total
    Exercise: $2.73Exp: 2010-10-01→ Common Stock (15,000 underlying)
Footnotes (5)
  • [F1]Disposed of pursuant to merger agreement between issuer and Celldex Therapeutics, Inc. in exchange for 8,217 shares of Celldex Therapeutics, Inc. common stock having a market value of $19.82 per share on the effective date of the merger, October 1, 2009.
  • [F2]This option, which vested 100% on May 2, 2007, was assumed by Celldex Therapeutics, Inc. in the merger and replaced with an option to purchase 4,108 shares of Celldex Therapeutics, Inc. common stock for $9.97 per share.
  • [F3]This option, which vested 100% on January 24, 2008, was assumed by Celldex Therapeutics, Inc. in the merger and replaced with an option to purchase 4,108 shares of Celldex Therapeutics, Inc. common stock for $2.52 per share.
  • [F4]This option, which vested 100% on May 21, 2008, was assumed by Celldex Therapeutics, Inc. in the merger and replaced with an option to purchase 4,108 shares of Celldex Therapeutics, Inc. common stock for $3.98 per share.
  • [F5]This option, which vested 100% on February 11, 2009, was assumed by Celldex Therapeutics, Inc. in the merger and replaced with an option to purchase 9,586 shares of Celldex Therapeutics, Inc. common stock for $2.08 per share.

Documents

1 file

Issuer

CURAGEN CORP

CIK 0001030653

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001030653

Filing Metadata

Form type
4
Filed
Oct 4, 8:00 PM ET
Accepted
Oct 5, 4:00 PM ET
Size
14.6 KB
View on SEC.gov